Syros Pharmaceuticals (SYRS) Misses Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Syros Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update
November 14, 2016 8:05 AM ESTInitiated Phase 2 Trial for SY-1425 in Genomically Defined Subsets of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Highlighted Research on First Selective CDK12 and CDK13 Inhibitor as Novel Approach to Treat Range of Cancers
Closed Initial Public Offering for $57.5 Million in Gross Proceeds
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS) today reported financial results for the quarter ended September 30, 2016 and provided an update on recent accomplishments and upcoming events.
With the dosing... More
